pharmtrace is an independent CRO providing strategies and solutions for clinical trials. pharmtrace offers flexible services and a global reach for studies with imaging endpoints, radiopharmaceuticals, and radiological interventional procedures. pharmtrace’s experienced team and international medical specialists network ensure that your investment in medical imaging, radiopharmaceuticals and radiological interventions delivers meaningful data. With our GCP compliant image management platform (ERICA) we support you to generate robust data to convince authorities and decision makers, and to achieve your development target. pharmtrace’s customers include biotech and academia, as well as internationally engaged pharmaceutical companies and device manufacturers. | Full-service clinical trial management by a team that understands imaging and radiopharmaceuticals as deeply as clinical operations. pharmtrace is a private, independent contract research organisation for the pharmaceutical and medical device industry. We focus on clinical studies where diagnostic imaging and/or nuclear medicine approaches are a major component for efficacy or safety assessment — including RECIST-based oncology trials, therapeutic radiopharmaceutical programmes, and medical device investigations. Our clients are global pharmaceutical companies, biotech firms, and academic sponsors across North America, Europe, and Australasia. We have managed clinical trials across oncology, neurology, cardiology, and other therapeutic areas — from first-in-human exploratory studies through Phase 3 registration trials and Phase 4 post-marketing commitments. In each, imaging expertise was built in from the protocol stage, not retrofitted. Our experience includes studies that have supported marketing authorisation applications to FDA and EMA. We know what these submissions require and design our processes accordingly from the outset. pharmtrace’s Imaging Core Lab provides comprehensive support for all imaging aspects of clinical trials and medical device investigations. Whether your study applies RECIST 1.1 or iRECIST for tumour response in oncology, PERCIST for PET-based assessment, quantitative MRI endpoints in neurology, SPECT imaging in cardiology, or quantitative imaging for a medical device investigation — we standardise, collect, quality-control, and independently review images with the rigour that regulatory submissions require. Our proprietary ERICA platform, validated to GAMP5 Category 5, serves as the single environment for DICOM image storage, technical and medical QC, and blinded read sessions — with per-study configuration validation for every project. We support sponsors at any stage — from early imaging strategy and endpoint selection through regulatory meeting preparation and marketing authorisation support. Our advice is grounded in operational experience, not theory.
NEUROPHET
NEUROPHET Inc., Seoul, Republic of Korea, with expertise in neuroscience. We have been focusing on developing and providing innovative medical solutions for helping patients suffering from neurological diseases. To achieve the mission, we have applied state-of-the-art AI technologies to our expertise in neuroimaging, brain modeling and neuromodulation. We are conducting research in imaging-based biomarkers for Alzheimer’s disease (AD), which will be valuable tool for clinical trials (surrogate biomarker for drug response and disease progression) and companion diagnostics for AD therapeutics and furthermore, global standardization for AD staging and diagnostics. Neurophet provides medical-grade solutions approved by international regulatory bodies. | Neurophet Inc. develops advanced AI-powered neuroimaging solutions to enhance the diagnosis, monitoring, and treatment planning of neurological disorders. Its flagship products—AQUA AD, AQUA, and SCALE PET—deliver precise, quantitative insights into brain atrophy, lesion dynamics, and imaging biomarkers, including those associated with amyloid-targeted therapeutics (ATT) and amyloid-related imaging abnormalities (ARIA), through MRI and PET imaging. | Neurophet is a specialized company developing AI-powered brain imaging analysis solutions and therapeutic medical devices, covering the full cycle of neurological care — from MRI and PET analysis to wearable brain stimulation devices. We support medical institutions with AI-based imaging for diagnosis and treatment monitoring, and provide standardized central imaging services for global pharmaceutical clinical trials through our Imaging Core Lab (ICL). From the clinical frontline to global clinical trials, Neurophet is advancing as a global leader in neurological imaging analysis.
Instant NanoBiosensors Co. Ltd
Instant NanoBiosensors (INB) is an innovative precision medicine company specializing in ultra-sensitive protein-based blood tests for Alzheimer’s disease and gene-based solutions for leukemia through its INLab NGS Solution. Revolutionizing Alzheimer’s Diagnostics Leveraging our proprietary Fiber Optic Particle Plasmon Resonance (FOPPR™) technology, we provide a non-invasive, rapid, and cost-effective solution for the early detection of Alzheimer’s-related biomarkers. Our technology enhances diagnostic accuracy, accelerates drug development, and supports personalized medicine applications for medical institutions and pharmaceutical companies. INB is the only point-of-care testing (POCT) platform on the market that enables end-to-end solutions—from antibody analysis to ultra-sensitive assay development. This platform has been adopted by the EU-funded TAuimMunE (TAME) project as a key training tool for PhD researchers. Current blood biomarker diagnostic methods are often expensive, centralized, and require specialized personnel to operate. INB’s solution addresses these limitations by making early Alzheimer’s detection more accessible and affordable. Our goal is to provide a highly accessible and precise diagnostic platform that enhances patient care and therapeutic outcomes worldwide. Leukemia Precision Medicine: INLab NGS Solution In leukemia diagnostics, INB has developed a comprehensive NGS Precision Medicine Solution that streamlines the entire workflow—from sample processing to final report generation—with fully integrated instruments, reagents, and software. We have extensive experience collaborating with National Taiwan University Hospital, working closely with hematology and oncology specialists to develop clinically relevant diagnostic reagents. Our solution currently serves nearly 70% of leukemia patients in Taiwan and has also been adopted by Yale Medical Center in the United States. Key Advantages of Our Solution ✅ Enhanced Accuracy and Efficiency: Our proprietary DimerOff™ technology minimizes primer dimer formation and sequencing noise, producing cleaner, more accurate sequencing data. This significantly improves sensitivity for detecting MDS/AML-related mutations, ensures higher clinical reliability, reduces sequencing costs by more than 50%, and shortens the turnaround time to just three days. ✅ MRD Detection & MPN Monitoring: Our solution enables precise monitoring of measurable residual disease (MRD) and myeloproliferative neoplasms (MPN), supporting long-term patient management and treatment adjustments. ✅ Customizable Panels for Specific Clinical Needs: We work closely with clinicians and researchers to develop NGS panels tailored to specific research and diagnostic requirements. Our flexible approach optimizes mutation detection, enhances patient stratification, and reduces operational costs for both research and clinical applications. Through continuous innovation and strategic partnerships, INB is committed to transforming precision medicine and improving patient outcomes worldwide. We Are Seeking Partnerships With: International Distributors interested in bringing our innovative diagnostic solutions to global markets. Biotech Companies looking for co-development opportunities in assay and panel development. Pharmaceutical Companies seeking companion diagnostics solutions to support targeted drug development. Hospitals & CROs aiming to establish a comprehensive precision medicine system within their organization. Scientists & Research Institutions interested in collaborative grant applications. If you are interested in collaborating with us, we welcome the opportunity to discuss how INB’s cutting-edge solutions can support your research, clinical, and commercial objectives.
iLoF
iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery and development. Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, and has been regularly featured by outlets like Tech Crunch, Wired, or Sifted as a rising star in AI-Driven Drug Discovery, Health Screening & Data Analytics.
CTCELLS
CTCELLS is an innovative cancer diagnostics and drug development company founded on the belief that effective cancer care requires solutions tailored to each individual. Powered by Circulating Tumor Cell (CTC) liquid biopsy, CTCELLS enables automated isolation of diverse CTC subtypes to better capture the full biological heterogeneity of cancer. To translate these insights into actionable research and clinical value, CTCELLS integrates its proprietary Continuous Centrifugal Microfluidics (CCM) technology for robust, automated CTC processing, lossless cell staining enabled by hydrogel-based HypICC to preserve cellular information for downstream analysis, and single-cell picking to support precise molecular profiling and functional characterization. By connecting cancer-specific cellular characteristics with the most suitable therapies, CTCELLS is committed to improving patient outcomes and accelerating the development of next-generation treatments, bringing new hope to patients facing difficult-to-treat cancers. | CTCELLS is an innovative biotechnology company striving for a total solution for cancer. With platform technologies in both therapeutics and diagnostics, the RACE platform is designed to deliver safer and more effective immunotherapies by optimizing the selection and administration of treatment based on a patient’s unique immunological profile. The TRACE Platform, on the other hand, is a cutting-edge liquid biopsy system that captures all types of Circulating Tumor Cells (CTCs). This allows for more precise diagnostics and treatment planning, targeting a range of cancer types. CTCELLS is committed to improving patient outcomes by integrating the latest in scientific research and technology into their products.
Celestia Diagnostics
Celestia Diagnostics develops lab tests and clinical bioinformatics systems to aid in the diagnosis and treatment of chronic complex conditions such as Long COVID, ME/CFS, and POTS.
CancerFree Biotech
CancerFree Biotech has a patented system to create patient-derived organoids (PDO) using a bionic tumor culture system, which can be used as an avatar to help physicians and patients develop the optimal cancer treatment strategy. The technology uses blood specimens, making it easy and non-intrusive, and has been successful in deriving 130+ different types of solid tumors from real-world cancer patients. CancerFree Biotech is also collaborating with pharmaceutical companies, using their PDO model to predict clinical trial outcomes during the drug development process, potentially helping to validate compounds during the preclinical and clinical trial phases. | CancerFree Biotech has developed a proprietary cancer cell culture system called E.V.A. (Ex Vivo Avatar). E.V.A. combines 3D cell culture scaffolding with AI image recognition to facilitate tumor cell proliferation. Using just 20mL of patient blood, the platform grows tumor cells to generate heterogeneous organoid models that closely mimic the patient’s internal tumor. These models allow pharmaceutical companies to identify the best candidates for clinical trials by validating the efficacy of their drugs in suppressing tumor cells from real patients. | CancerFree Biotech has developed Prometheus Lab AI, a smart-glasses platform that automates R&D lab documentation. With hands-free, real-time workflow capture, Prometheus converts visual input into structured experiment records, reducing manual errors and significantly cutting down on documentation time.